1. Immunology/Inflammation NF-κB
  2. Interleukin Related NF-κB
  3. MOR-106

MOR-106  (Synonyms: MOR12743; MOR03207)

Cat. No.: HY-P991598
Technical Support

MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis.

For research use only. We do not sell to patients.

MOR-106 Chemical Structure

MOR-106 Chemical Structure

CAS No. : 2304625-87-2

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis[1][2].

Isotype

Human IgG1 kappa

Recommend Isotype Controls
IC50 & Target[1][2]

NF-κB

 

IL-17C

 

In Vitro

MOR-106 (0.00001-1 nM, 30 min) potently blocks the interaction of human (IC50 = 59 pM) and mouse (IC50 = 55 pM) IL-17C to IL-17RE[1].
MOR-106 (0.0001-1 μg/mL, 30 min) significantly inhibits IL-17C induced activation of NF-κB signaling pathway in NIH3T3 cells[1].
MOR-106 (0.001-1 μg/mL, 48 h) significantly inhibits the expression of DEFB4A and CSF3 induced by IL-17C and TNF-α in human and mouse primary keratinocytes[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR[1]

Cell Line: human and mouse primary keratinocytes
Concentration: 0.001-1 μg/mL
Incubation Time: 48 h
Result: Significantly reduced the level of DEFB4A and CSF3.
In Vivo

MOR-106 (10 mg/kg, i.p., 3 days before and just before the first injection of IL-23) significantly reduces IL-23-induced skin inflammation in female BALB/c mice[1].
MOR-106 (0.4-50 mg/kg, i.p., 3 days before, at the start, and 4 days after the first application of MC903) effectively alleviates MC903 induced atopic dermatitis and atopic eczema in female BALB/c mice[1][2].
MOR-106 (3 and 30 mg/kg, i.p., twice weekly, for 6 weeks) alleviates spontaneous atopic dermatitis in Flaky tail mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: IL-23 (1 μg, for 4 consecutive days) injeceted female BALB/c mice (8 weeks)[1]
Dosage: 10 mg/kg
Administration: Intraperitoneal injection (i.p.), 3 days before and just before the first injection of IL-23
Result: Significantly reduced ear swelling and epidermal thickening.
Reduced the expression of inflammatory factors such as IL-17A, IL-22, IL-1β, LCN2, S100A8 and S100A9.
Animal Model: Topical administration of 2 nM MC903 (HY-10001) for 5 days to female BALB/c mice (8 weeks)[1][2]
Dosage: 0.4, 2, 10 and 50 mg/kg
Administration: Intraperitoneal injection (i.p.), 3 days before, at the start, and 4 days after the first application of MC903
Result: Dose dependently reduced ear swelling and epidermal thickening.
Reduced TSLP, IL-33, and CCL17 levels.
Significantly reduced skin infiltration of T cells, eosinophils, and neutrophils.
Animal Model: Flaky tail mice on a congenic C57BL/6J background[1]
Dosage: 3 and 30 mg/kg
Administration: Intraperitoneal injection (i.p.), twice weekly for 6 weeks
Result: Significantly reduced skin inflammation score.
Reduced the number of mast cells and serum IgE levels.
Reduced the expression of IL-4, IL-17A, CCL17 and IFN-γ.
Gene ID

27189  [NCBI]

Accession
Target

IL-17C

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

CAS No.
SMILES

N/A

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
MOR-106
Cat. No.:
HY-P991598
Quantity:
MCE Japan Authorized Agent: